Best Case
15%FDA approves daraxonrasib quickly after a clean priority review, expanded access reaches a meaningful share of eligible U.S. patients, and the model is copied for other lethal cancers.
Forecast dossier
FDA will use expanded access as a bridge to priority oncology approvals
The FDA's May 1 safe-to-proceed letter for Revolution Medicines' daraxonrasib expanded-access protocol, issued two days after submission, is likely to become a template for allowing broader pre-approval access to high-signal cancer drugs already moving through expedited review paths. The causal signal is stronger because daraxonrasib also has Breakthrough Therapy and Orphan Drug designations, Revolution Medicines reported pivotal Phase 3 survival benefit on April 13, 2026, and the drug is linked to the Commissioner's National Priority Voucher pilot program.
Verdict: Likely, but bounded. The strongest forecast is not that daraxonrasib will be approved, but that FDA will more often pair expedited oncology review with broader pre-approval access when late-stage evidence, unmet need, and sponsor readiness align.
Date
May 1, 2026
Reliability
72
Harm potential
Medium
Scenario odds
Baseline
50%Expanded access remains controlled but visible, daraxonrasib proceeds through priority review, and FDA uses similar bridges selectively for oncology drugs with compelling late-stage evidence.
Adverse Case
25%Safety, manufacturing, eligibility, or confirmatory-data concerns limit access and make FDA more cautious about repeating fast treatment-protocol clearance.
Wildcard
10%Political or legal scrutiny of pre-approval access pressures FDA to formalize a new public framework for when broad expanded access should accompany expedited drug review.
Timeline projections
1-Year
Selective replication begins
Developments: FDA clears a small number of similar oncology expanded-access protocols for drugs with strong pivotal data or breakthrough status.
Risks: A serious adverse-event signal or supply shortage could narrow eligibility.
Outlook: The approach becomes visible but not routine.
2-Year
Operational norms emerge
Developments: Sponsors seeking expedited oncology review increasingly prepare expanded-access plans earlier in development.
Risks: Uneven access across hospitals and insurers creates criticism.
Outlook: Expanded access becomes a planning item for priority oncology filings.
3-Year
Protocol bridge becomes semi-standard
Developments: FDA may publish clearer expectations for treatment-protocol access around high-unmet-need oncology applications.
Risks: If several bridged drugs disappoint after approval, FDA may tighten standards.
Outlook: The model persists for selected cancers rather than all expedited drugs.
5-Year
Evidence-linked access framework
Developments: Pre-approval oncology access is more often tied to measurable evidence thresholds, safety monitoring, and sponsor supply commitments.
Risks: Litigation or congressional pressure could either force expansion or impose tighter limits.
Outlook: The system becomes more formal and data-driven.
10-Year
Integrated approval-access pathway
Developments: For some lethal diseases, expanded access, real-world evidence capture, and priority review may be integrated into a single regulatory operating model.
Risks: Data quality from expanded access may remain too inconsistent for broad regulatory reliance.
Outlook: The model is durable if it improves access without undermining evidence quality.
20-Year
Adaptive oncology access norm
Developments: Patients outside trials may routinely enter regulated access-and-monitoring programs before final approval for select molecularly targeted therapies.
Risks: Equity gaps and sponsor discretion could remain persistent weaknesses.
Outlook: The boundary between late-stage trials, expanded access, and early commercial use becomes more managed but less rigid.
50-Year
Pre-approval access as a regulated care layer
Developments: Highly personalized oncology may rely on continuously monitored access pathways rather than a single approval moment for every indication.
Risks: Long-term governance could fail if commercial incentives dominate evidence generation.
Outlook: A mature system would treat early access as conditional, monitored, and revocable.
Planning prompts to verify
- Track whether FDA posts the daraxonrasib protocol details and patient eligibility criteria in May 2026.
- Monitor Revolution Medicines' new drug application timing and whether it is formally reviewed through the voucher pathway.
- Compare the next five oncology expanded-access treatment protocols for review speed, eligibility breadth, and later approval outcomes.